Investors Buy Shares of Pfizer (PFE) on Weakness Following Insider Selling

Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Monday following insider selling activity. $90.14 million flowed into the stock on the tick-up and $68.22 million flowed out of the stock on the tick-down, for a money net flow of $21.92 million into the stock. Of all stocks tracked, Pfizer had the 13th highest net in-flow for the day. Pfizer traded down ($0.07) for the day and closed at $37.13Specifically, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. In the last three months, insiders sold 36,800 shares of company stock worth $1,327,248. Insiders own 0.06% of the company’s stock.

Several brokerages have recently issued reports on PFE. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Barclays set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $38.77.

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $221,708.50, a P/E ratio of 14.88, a price-to-earnings-growth ratio of 2.63 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the previous year, the company earned $0.61 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 79.01%.

Pfizer announced that its Board of Directors has approved a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Several large investors have recently modified their holdings of PFE. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer in the second quarter valued at about $103,000. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new position in shares of Pfizer in the second quarter valued at about $120,000. Finally, Americafirst Capital Management LLC bought a new position in shares of Pfizer in the third quarter valued at about $127,000. Institutional investors own 69.75% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/12/20/investors-buy-shares-of-pfizer-pfe-on-weakness-following-insider-selling.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply